[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558935":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":7,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Hunan Cancer Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","18F-FAPI-04","18F-FAPI-04 was injected into the patients before the PET\u002FCT or PET\u002FMR scans",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Hui Ye, PhD","CONTACT","13755117105","yehui@hnca.org.cn",[20],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Hunan Cancer hospital","RECRUITING","Changsha","Hunan","410000","China","CN",{"type":29,"coordinates":30},"Point",[31,32],112.97087,28.19874,{"lat":32,"lon":31},[35],{"name":15,"role":16,"phone":36,"phoneExt":7,"email":18},"86-13755117105",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Hui Ye","Professor","100558935","18f-fapi-04-petct-and-petmr-in-patients-with-various-types-of-malignant-tumors-100558935",false,"NCT06557590","18F-FAPI-04 PET\u002FCT and PET\u002FMR in Patients With Various Types of Malignant Tumors","Preliminary Study on the Diagnostic Value of 18F-FAPI-04 PET\u002FCT and PET\u002FMR in Patients With Various Types of Malignant Tumors","Inclusion Criteria:\n\npatients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\npatients with non-malignant lesions; patients with pregnancy; the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","90 Years",{"count":53,"type":54},500,"ESTIMATED","OBSERVATIONAL","To evaluate the potential usefulness of 18F-FAPI-04 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) and positron emission tomography\u002Fmagnetic resonance imaging （PET\u002FMR）for the diagnosis of primary and metastatic lesions, detection of recurrence or assessment of pathologic response in various types of cancer.",[58,59],"Cancer","FAP","2024-08-14",{"date":62,"type":63},"2024-08-16","ACTUAL",{"date":65,"type":63},"2024-01-01",{"date":67,"type":54},"2028-12-31",{"name":5,"class":6},1]